<DOC>
	<DOCNO>NCT00292253</DOCNO>
	<brief_summary>This randomize , multicenter , parallel-group , open-label study compare tolerability Rebif® injection ( 44 microgram [ mcg ] administer subcutaneously three time week ) without Rebiject™Mini , auto-injection device relapsing-remitting multiple sclerosis ( MS ) subject . Subjects randomly assign either one two Rebif® group 1:1 ratio Study Day 1 stratify center . Subjects receive minimum 3 month treatment Rebif® 44 mcg three time week ask assess injection site reaction weekly basis . Clinic visit occur 1 3 month initiation treatment .</brief_summary>
	<brief_title>Tolerability Rebif® Injection With Without Use Rebiject™Mini Relapsing-Remitting Multiple Sclerosis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Greater equal 18 year age Has relapsingremitting MS Are willing able comply protocol duration study Has significant leukopenia/lymphopenia ( white blood cell count le ( &lt; ) 0.5 time low limit normal ) Has elevate liver function test ( aspartate aminotransferase [ AST ] , Alanine transaminase [ ALT ] , alkaline phosphatase great ( &gt; ) 2 time upper limit normal total bilirubin &gt; 1.5 time upper limit normal ) Has allergy human serum albumin mannitol Had treatment investigational product procedure within 3 month Has presence systemic disease abnormal laboratory finding might interfere subject safety , compliance evaluation condition study Has concomitant use Avonex® , Betaseron® , Copaxone® , Novantrone®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>MS</keyword>
</DOC>